Pre-operative prostate cancer nomograms - Evidencio
Pre-operative prostate cancer nomograms
This model contains a complete overview of all clinically useful risk prediction models. The models predict the risk of: 
  • Organ confined disease
  • Lymph node involvement
  • Seminal Vesicle involvement
  • Extraprostatic Extension
Research authors: None
Version: 1.12
  • Public
  • Urology
  • Composite Algorithm
  • Details
  • Save input
  • Load input

Number of positive biopsy cores

0
20
cores

Number of negative biopsy cores

0
20
cores

PSA

0
50
ng/ml

Primary gleason score

Secondary gleason score

Gleason sum score

Clinical tumor stage

Percentage of positive cores with highest-grade PCa

0
100
%

Percentage of positive cores with lower grade PCa

0
100
%
MSKCC Nomogram: Probability of organ-confined disease in prostate cancer patients (includes biopsy cores)
Probability of organ-confined disease: ...

Partin Tables update 2007: Organ confined disease
Calculated risk for organ confined disease is: ... %

Partin Tables update 2013: Organ confined disease
The calculated risk for organ confined disease is: ... %

Partin Tables update 2016: Organ confined disease
Calculated risk for organ confined disease is: ... %

MSKCC nomogram: Probability of extracapsular extension in prostate cancer patients (includes biopsy cores)
Probability of extracapsular extension: ...

Partin Tables update 2007: Extraprostatic extension
Calculated risk for extraprostatic extension is: ... %

Partin Tables update 2013: Extraprostatic extension
The calculated risk for Extraprostatic Extension is: ... %

Partin Tables update 2016: Extraprostatic Extension
Calculated risk for extraprostatic extension is: ... %

Roach formula (Capsular penetration)
Calculated risk for capsular penetration ... %

MSKCC nomogram: Probability of seminal vesicle invasion in prostate cancer patients (includes biopsy cores)
Probability of seminal vesicle invasion: ...

Partin Tables update 2007: Seminal vesicle involvement
Calculated risk for seminal vesicle involvement is: ... %

Partin Tables update 2013: Seminal vesicle invasion
The calculated risk for Seminal Vesicle Invasion is: ... %

Partin Tables update 2016: Seminal vesicle involvement
Calculated risk for seminal vesicle involvement is: ... %

Roach formula (Seminal Vesicle)
Calculated risk for Seminal Vesicle invasion is: ... %

MSKCC Nomogram: Probability of lymph node involvement in prostate cancer patients (includes biopsy cores)
The calculated probability of lymph node involvement is: ...

Partin Tables update 2007: Lymph node involvement
Calculated risk for lymph node involvement is: ... %

Partin Tables update 2013: Lymph node involvement
The calculated risk for lymph node involvement is: ... %

Partin Tables update 2016: Lymph node involvement
Calculated risk for lymph node involvement is: ... %

Briganti 2012 Nomogram: "Prediction of Lymph Node Involvement in patients with prostate cancer"
The calculated probability of lymph node involvement is: ...

Novel Briganti nomogram: Predicting the risk of lymph node involvement in prostate cancer patients
The calculated risk of lymph node involvement is: ...

Yale formula (update of the Roach formula).
The calculated probability of lymph node involvement is: ... %

Roach formula (Lymph Node involvement)
Calculated risk for Lymph Node Involvement is: ... %

Winter nomogram: Predicting lymph node involvement through sentinel guided pelvic lymph node dissection (SPLND)
Calculated risk for lymph node involvement is: ...

This algorithm is provided for educational, training and information purposes. It must not be used to support medical decision making, or to provide medical or diagnostic services. Read our full Disclaimer.

Recent algorithms
Underlying algorithms
MSKCC Nomogram: Probability of organ-confined disease in prostate cancer patients (includes biopsy cores)
Calculates the probability that the cancer will be found to be confined to the prostate gland when the prostate is removed (c-index: 0.71). This model includes biopsy cores. 

Disqualifying treatments: This model does not apply to patients who underwent preoperative hormone- or radiation therapy for prostate cancer. 
Research authors: Source: Memorial Sloan Kettering Cancer Center (US)
Partin Tables update 2007: Organ confined disease
Data for the original Partin tables were collected from men treated from 1982 to 1991. A multi-institutional update was performed 4 years later, based on data from 1982 to 1996. A further update accounting for continuing stage migration was made in 2001, examining patients from 1994 to 2000. This model has been validated in various clinical settings, from academic medical centers in the United States, Canada, and Turkey to cohorts of community patients.
Research authors: Danil V. Makarov, Bruce J. Trock, Elizabeth B. Humphreys, Leslie A. Mangold, Patrick C. Walsh, Jonathan I. Epstein, Alan W. Partin
Partin Tables update 2013: Organ confined disease
Objective was to update the 2007 Partin tables in a contemporary
patient population.
Pathological stage after radical prostatectomy can be accurately predicted by serum prostate-specific antigen level, clinical stage and biopsy Gleason sum, the ‘Partin tables’. Since the previous publication of the Partin tables, an updated Gleason scoring system has been established and incremental changes have occurred in the clinical characteristics of patients diagnosed with prostate cancer. The current analysis updates the Partin nomogram in a contemporary cohort of patients.
Research authors: John B. Eifler, Zhaoyang Feng, Brian M. Lin, Michael T. Partin, Elizabeth B. Humphreys, Misop Han, Jonathan I. Epstein, Patrick C. Walsh, Bruce J. Trock, Alan W. Partin
Partin Tables update 2016: Organ confined disease
Objective of the study was to update the Partin Tables for prediction of pathological stage in the contemporary setting and examine trends in patients treated with radical prostatectomy (RP) over the past
three decades.
Research authors: Jeffrey T. Tosoian, Meera Chappidi, Zhaoyong Feng, Elizabeth B. Humphreys, Misop Han, Christian P. Pavlovich, Jonathan I. Epstein, Alan W. Partin, Bruce J. Trock
MSKCC nomogram: Probability of extracapsular extension in prostate cancer patients (includes biopsy cores)
Calculates the probability of “extracapsular extension,” meaning the probability that the cancer extends through the capsule of the prostate into the surrounding tissue (c-index: 0.70). This model includes biopsy cores. 

Disqualifying treatments
: This model does not apply to patients who underwent preoperative hormone- or radiation therapy for prostate cancer. 
Research authors: Source: Memorial Sloan Kettering Cancer Center (US)
Partin Tables update 2007: Extraprostatic extension
Data for the original Partin tables were collected from men treated from 1982 to 1991. A multi-institutional update was performed 4 years later, based on data from 1982 to 1996. A further update accounting for continuing stage migration was made in 2001, examining patients from 1994 to 2000. This model has been validated in various clinical settings, from academic medical centers in the United States, Canada, and Turkey to cohorts of community patients.
Research authors: Danil V. Makarov, Bruce J. Trock, Elizabeth B. Humphreys, Leslie A. Mangold, Patrick C. Walsh, Jonathan I. Epstein, Alan W. Partin
Partin Tables update 2013: Extraprostatic extension
Objective was to update the 2007 Partin tables in a contemporary
patient population.
Pathological stage after radical prostatectomy can be accurately predicted by serum prostate-specific antigen level, clinical stage and biopsy Gleason sum, the ‘Partin tables’. Since the previous publication of the Partin tables, an updated Gleason scoring system has been established and incremental changes have occurred in the clinical characteristics of patients diagnosed with prostate cancer. The current analysis updates the Partin nomogram in a contemporary cohort of patients.
Research authors: John B. Eifler, Zhaoyang Feng, Brian M. Lin, Michael T. Partin, Elizabeth B. Humphreys, Misop Han, Jonathan I. Epstein, Patrick C. Walsh, Bruce J. Trock, Alan W. Partin
Partin Tables update 2016: Extraprostatic Extension
Objective of the study was to update the Partin Tables for prediction of pathological stage in the contemporary setting and examine trends in patients treated with radical prostatectomy (RP) over the past
three decades.
Research authors: Jeffrey T. Tosoian, Meera Chappidi, Zhaoyong Feng, Elizabeth B. Humphreys, Misop Han, Christian P. Pavlovich, Jonathan I. Epstein, Alan W. Partin, Bruce J. Trock
Roach formula (Capsular penetration)
A simple equation for estimating the risk of capsular penetration was derived from a nomogram published by Partin et al. demonstrating the value of combining the pre-treatment prostate specific antigen and Gleason Score in predicting the risk of capsular penetration for patients with clinically localized prostate cancer. The risk of positive capsular penetration (CP+) was calculated using the equation; CP+ = (1.5 * (PSA)) + (10 * ((Gleason score) - 3))
Research authors: Mack Roach III
MSKCC nomogram: Probability of seminal vesicle invasion in prostate cancer patients (includes biopsy cores)
Calculates the probability that prostate cancer has spread to one or both seminal vesicles (c-index: 0.85). This model includes biopsy cores. 

Disqualifying treatments: This model does not apply to patients who underwent preoperative hormone- or radiation therapy for prostate cancer. 
Research authors: Source: Memorial Sloan Kettering Cancer Center (US)
Partin Tables update 2007: Seminal vesicle involvement
Data for the original Partin tables were collected from men treated from 1982 to 1991. A multi-institutional update was performed 4 years later, based on data from 1982 to 1996. A further update accounting for continuing stage migration was made in 2001, examining patients from 1994 to 2000. This model has been validated in various clinical settings, from academic medical centers in the United States, Canada, and Turkey to cohorts of community patients.
Research authors: Danil V. Makarov, Bruce J. Trock, Elizabeth B. Humphreys, Leslie A. Mangold, Patrick C. Walsh, Jonathan I. Epstein, Alan W. Partin
Partin Tables update 2013: Seminal vesicle invasion
Objective was to update the 2007 Partin tables in a contemporary
patient population.
Pathological stage after radical prostatectomy can be accurately predicted by serum prostate-specific antigen level, clinical stage and biopsy Gleason sum, the ‘Partin tables’. Since the previous publication of the Partin tables, an updated Gleason scoring system has been established and incremental changes have occurred in the clinical characteristics of patients diagnosed with prostate cancer. The current analysis updates the Partin nomogram in a contemporary cohort of patients.
Research authors: John B. Eifler, Zhaoyang Feng, Brian M. Lin, Michael T. Partin, Elizabeth B. Humphreys, Misop Han, Jonathan I. Epstein, Patrick C. Walsh, Bruce J. Trock, Alan W. Partin
Partin Tables update 2016: Seminal vesicle involvement
Objective of the study was to update the Partin Tables for prediction of pathological stage in the contemporary setting and examine trends in patients treated with radical prostatectomy (RP) over the past
three decades.
Research authors: Jeffrey T. Tosoian, Meera Chappidi, Zhaoyong Feng, Elizabeth B. Humphreys, Misop Han, Christian P. Pavlovich, Jonathan I. Epstein, Alan W. Partin, Bruce J. Trock
Roach formula (Seminal Vesicle)
A simple equation for estimating the risk of seminal vesicle invasion was derived from a nomogram published by Partin et al. demonstrating the value of combining the pre-treatment prostate specific antigen and Gleason Score in predicting the risk of seminal vesicle invasion for patients with clinically localized prostate cancer. The risk of positive seminal vesicles (SV+) was calculated using the equation; SV+ = (PSA) + (10 * ((Gleason score) - 6)).
Research authors: Mack Roach III
MSKCC Nomogram: Probability of lymph node involvement in prostate cancer patients (includes biopsy cores)
Calculates the probability that prostate cancer has spread to the pelvic lymph nodes (c-index: 0.86). This model includes biopsy cores. 

Disqualifying treatments: This model does not apply to patients who underwent preoperative hormone- or radiation therapy for prostate cancer. 
Research authors: Source: Memorial Sloan Kettering Cancer Center (US)
Partin Tables update 2007: Lymph node involvement
Data for the original Partin tables were collected from men treated from 1982 to 1991. A multi-institutional update was performed 4 years later, based on data from 1982 to 1996. A further update accounting for continuing stage migration was made in 2001, examining patients from 1994 to 2000. This model has been validated in various clinical settings, from academic medical centers in the United States, Canada, and Turkey to cohorts of community patients.
Research authors: Danil V. Makarov, Bruce J. Trock, Elizabeth B. Humphreys, Leslie A. Mangold, Patrick C. Walsh, Jonathan I. Epstein, Alan W. Partin
Partin Tables update 2013: Lymph node involvement
The objective of this study was to update the 2007 Partin tables in a contemporary patient population. Pathological stage after radical prostatectomy can be accurately predicted by serum prostate-specific antigen level, clinical stage and biopsy Gleason sum, the ‘Partin tables’. Since the previous publication of the Partin tables, an updated Gleason scoring system has been established and incremental changes have occurred in the clinical characteristics of patients diagnosed with prostate cancer. The current analysis updates the Partin nomogram in a contemporary cohort of patients.
Research authors: John B. Eifler, Zhaoyang Feng, Brian M. Lin, Michael T. Partin, Elizabeth B. Humphreys, Misop Han, Jonathan I. Epstein, Patrick C. Walsh, Bruce J. Trock, Alan W. Partin
Partin Tables update 2016: Lymph node involvement
Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era (Lymph node involvement)

Objective of the study was to update the Partin Tables for prediction of pathological stage in the contemporary setting and examine trends in patients treated with radical prostatectomy (RP) over the past
three decades.
Research authors: Jeffrey T. Tosoian, Meera Chappidi, Zhaoyong Feng, Elizabeth B. Humphreys, Misop Han, Christian P. Pavlovich, Jonathan I. Epstein, Alan W. Partin, Bruce J. Trock
Briganti 2012 Nomogram: "Prediction of Lymph Node Involvement in patients with prostate cancer"
Research authors: Alberto Briganti, Allesandro Larcher, Firas Abdollah, Umberto Capitanio, Andrea Gallina, Nazareno Suardi, Marco Bianchi, Maxine Sun, Massimo Freschi, Andrea Salonia, Pierre I Karakiewicz, Patrizio Rigatti, Francesco Montorsi
Novel Briganti nomogram: Predicting the risk of lymph node involvement in prostate cancer patients
Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.​​​​​

Several previous nomograms have been developed by Briganti et al. that predict a patients risk of lymph node involvement. This model is an update of the Briganti nomogram and showed a better performance than the previous Briganti nomogram. This model added the percentage of biopsy cores with highest grade PCa and lowest grade PCa as new predictors to the prediction of lymph node involvement. 

Previous Briganti nomogram can be found here: http://www.evidencio.com/public/show/670
Research authors: Giorgio Gandaglia, Nicola Fossati, Emanuele Zaffuto, Marco Bandini, Paolo Dell'Oglio, Carlo Andrea Bravi, Giuseppe Fallara, Francesco Pellegrino, Luigi Nocera, Pierre I. Karakiewicz, Zhe Tian, Massimo Freschi, Rodolfo Montironi, Francesco Montorsi, Alberto Briganti
Yale formula (update of the Roach formula).
A new formula for prostate cancer lymph node risk
Many investigators have created tools for predicting extraprostatic disease and lymph node (LN) involvement. One widely used tool is a linear formula created by Roach et al. the Roach formula (RF), which defines the risk of pelvic LN as follows: (% pelvic LN risk = prostate-specific antigen [PSA])2/3 + (Gleason – 6))10). There has been significant stage migration in prostate cancer over the past decade since the creation of the RF. To provide clinicians with a practical approach to estimating LN risk that was developed from a population-based sample of patients who reflect the vast majority of patients diagnosed in the modern PSA era, and whose care reflects current patterns of care, we developed and validated a new predictive formula using the SEER database. A fast, accurate, and easy-to-use formula would be helpful in discussing LN risk with patients and in the conceptualization of LN risk for future clinical trials.
Research authors: James B. Yu, Danil V. Makarov, Cary Gross
Roach formula (Lymph Node involvement)
A simple equation for estimating the risk of positive lymph nodes was empirically derived from a nomogram published by Partin et al. demonstrating the value of combining the pre-treatment prostate specific antigen and Gleason Score in predicting the risk of lymph node metastasis for patients with clinically localized prostate cancer. The risk of positive nodes (NS) was calculated using the equation; N+ = (2/3*PSA) + (GS - 6) X 10, where PSA and GS are the pre-treatment prostate specific antigen and Gleason Score respectively, and the calculated risk is constrained between O-65% for a PSA < 40 ng/ml (as in the nomogram).
Research authors: Mack Roach III, Carol Marquez, Hae-Sook Yuo, Perinchery Narayan, Lorie Coleman, Unyime O. Nseyo, Zarrin Navvar, Peter R. Carrol
Winter nomogram: Predicting lymph node involvement through sentinel guided pelvic lymph node dissection (SPLND)
Existing nomograms predicting lymph node involvement (LNI) in prostate cancer (PCa) are based on conventional lymphadenectomy. The aim of the study was to develop the first nomogram for predicting LNI in PCa patients undergoing sentinel guided pelvic lymph node dissection (sPLND).
Research authors: Alexander Winter, T. Kneib, M. Rohde, R.P. Henke, F. Wawroschek
Comments

Algorithm feedback

3 Comments
On 2018-05-11 11:13:59 ColletteE wrote:
Beste Tom, hele gave tool een mooi compleet! Groet Eelco
On 2018-06-01 16:52:52 sbstrum wrote:
Tom, not sure where the input "Percentage of positive cores with highest-grade PCa" and the "Percentage of positive cores with lower grade PCa" is coming from. How did you interpret this and from what input? <br /> <br /> Will we be able to see the various authors results for OCD (organ-confined disease), capsular penetration (CP) etc be shown side by side on a bar graph?
On 2018-06-01 16:54:05 sbstrum wrote:
One other item, when can the downloaded report be obtained?
Evidencio v3.36 © 2015 - 2025 Evidencio. All Rights Reserved